The Dott. Dino Paladin Company operates in the following sectors:
- Development and pilot production of biotechnology and nanotechnology products, particularly the development and patenting of drugs currently in production by another company; it has collaborated in research contract projects to develop more than 100 medical-diagnostic devices in-vitro labelled CE (CE IVD) in molecular biology.
Production, installation, repair and maintenance of medical instruments and software for:
- molecular diagnosis;
- devices for analysis and research;
- tracing of workflow and samples in pathological anatomies;
- development of products for the realisation and management of biobanks.
- The company has solid research-and-development (R&D) experience in the field of human diagnostics, having collaborated with various universities in the study of tumour drug resistance, HLA typing, genetic diseases and viral typing to acquire and consolidate knowledge for avant-garde molecular biology techniques.
In compliance with its mission, the Engineering and Architecture Department (DIA) of the University of Trieste prepares highly professional individuals and provides technical-scientific support to the economy of a large territory, whose backbone is composed of large international companies, a network of medium and small businesses and an infra-structural system with several transport and logistics companies.
Thanks to its wide and rich range of skills, the University offers didactic activities, scientific research, technology transfer and knowledge, as well as four three-year degree courses, nine specialised degree courses and a one-cycle degree course in Architecture.
The Department’s activities concern numerous research areas and are conducted in various sectors, including energy, the environment, process and product analysis, information and communication technologies and biomedical applications, in which the involved research group operates with proven skills in the field of Raman and SERS spectroscopy.
The Fund for Liver Diseases - Fondo per le Malattie del Fegato (founded in 1989) founded the Italian Liver Foundation - Fondazione Italiana Fegato ONLUS (FIF) in 2008. The FIF was the first Italian institution to combine basic research and clinical activity in the field of liver disease. The main purpose of the FIF is promoting translational research to bring the results of molecular research into clinical practice. Furthermore, FIF provides an intensive educational support by hosting many students and researchers from all over the world.
The Italian Liver Foundation finances its activities with institutional funds from its public and private partners and with ad hoc funding for research projects. Currently, the FIF staff is composed of three senior researchers, one administrative secretary, one laboratory technician, six post-doctoral researchers and two graduate students.
The FIF boasts numerous collaborations with research institutions and hospitals at the national and international levels, including the University of Ljubljana; the University of Prague; Fundación Favaloro; Buenos Aires and Centro Binacional de Criobiología Clínica y Aplicada, Rosario (Argentina); Universidad National Autonoma Mexico City (DF Mexico); the Eijkman Institute for Molecular Biology and Medicine, Jakarta (Indonesia); The Children Mercy Hospital, Kansas City (USA).
Alphagenics is one of the most qualified national companies in the use of innovative molecular biology techniques, suitable both for clinical use and research in the medical and environmental fields, for the in-depth analysis of prognostic/diagnostic issues.
Aphagenics focuses on the research, development and production of testing kits. The company provides consulting services for the technology transfer of new projects, and its R&D department is engaged in the development of new technologies and the design of custom solutions to fully meet the market’s needs. The company has developed different systems for the molecular typing and quantification of viral genomes (HPV/HCV) using reverse dot/blot, real-time PCR and ELISA methodologies. The company also offers a full panel of prognostic kits, based mainly on real-time PCR technology, for some of the most important cancers, such as kits for colon and gastric carcinoma (ARKRAS e ACMSi), thyroid, colon and melanoma cancer (ARBRAF), glioblastoma (ARMGMt), lung cancer (A lEGFR) and an innovative prognostic kit that provides the probability of breast cancer recurrence (ARBREASt). Tests are highly reproducible, sensitive and rapid.
Insiel Mercato develops e-health and e-government solutions that enable healthcare and public administration organisations to offer the best services to the communities in which they operate, enabling citizens to become leaders in exercising their rights. With over 1,000 customers and more than 200 employees, Insiel Market is a leading company in Italy’s IT sector.